Cargando…

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

BACKGROUND: Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. Cariprazine is a potent dopamine D(3) and D(2) receptor partial agonist that is FDA-approved in the US for the treatment of schizoph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasrallah, Henry A., Earley, Willie, Cutler, Andrew J., Wang, Yao, Lu, Kaifeng, Laszlovszky, István, Németh, György, Durgam, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571492/ https://www.ncbi.nlm.nih.gov/pubmed/28836957 http://dx.doi.org/10.1186/s12888-017-1459-z

Ejemplares similares

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
por: Durgam, Suresh, et al.
Publicado: (2016)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
por: Laszlovszky, I., et al.
Publicado: (2021)

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
por: Patel, Mehul, et al.
Publicado: (2020)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
por: McIntyre, Roger S., et al.
Publicado: (2020)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Publicado: (2021)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
por: Rancans, Elmars, et al.
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
por: Kane, John M, et al.
Publicado: (2021)

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
por: Earley, Willie R., et al.
Publicado: (2019)

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
por: Yatham, Lakshmi N., et al.
Publicado: (2020)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam, Suresh, et al.
Publicado: (2017)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
por: Bajouco, Miguel, et al.
Publicado: (2022)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Cariprazine pharmacokinetics
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_obhk5ad03v3mjmqh9a8ui35nd1